Russell Investments Group Ltd. Has $879,000 Stake in TELA Bio, Inc. (NASDAQ:TELA)

Russell Investments Group Ltd. lifted its stake in TELA Bio, Inc. (NASDAQ:TELAFree Report) by 25.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,619 shares of the company’s stock after purchasing an additional 16,588 shares during the period. Russell Investments Group Ltd. owned 0.43% of TELA Bio worth $879,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. State Street Corp increased its holdings in shares of TELA Bio by 9.1% in the first quarter. State Street Corp now owns 26,065 shares of the company’s stock valued at $303,000 after purchasing an additional 2,167 shares in the last quarter. BlackRock Inc. boosted its stake in TELA Bio by 17.6% in the third quarter. BlackRock Inc. now owns 17,203 shares of the company’s stock valued at $146,000 after acquiring an additional 2,578 shares during the last quarter. Morgan Stanley boosted its stake in TELA Bio by 38,708.3% in the fourth quarter. Morgan Stanley now owns 4,657 shares of the company’s stock valued at $54,000 after acquiring an additional 4,645 shares during the last quarter. Kamunting Street Capital Management L.P. boosted its stake in TELA Bio by 5.0% in the fourth quarter. Kamunting Street Capital Management L.P. now owns 136,500 shares of the company’s stock valued at $1,570,000 after acquiring an additional 6,500 shares during the last quarter. Finally, Calamos Advisors LLC boosted its stake in TELA Bio by 63.1% in the first quarter. Calamos Advisors LLC now owns 16,840 shares of the company’s stock valued at $179,000 after acquiring an additional 6,512 shares during the last quarter. Institutional investors and hedge funds own 68.13% of the company’s stock.

TELA Bio Price Performance

Shares of TELA stock opened at $9.54 on Friday. TELA Bio, Inc. has a 52-week low of $6.40 and a 52-week high of $13.18. The stock has a market cap of $233.61 million, a PE ratio of -4.24 and a beta of 0.93. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.75 and a current ratio of 6.84. The firm’s 50 day moving average price is $9.63 and its two-hundred day moving average price is $10.14.

TELA Bio (NASDAQ:TELAGet Free Report) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.12. The firm had revenue of $14.49 million for the quarter, compared to analysts’ expectations of $14.60 million. TELA Bio had a negative net margin of 88.46% and a negative return on equity of 215.52%. As a group, analysts forecast that TELA Bio, Inc. will post -2.15 EPS for the current year.

TELA Bio Company Profile

(Free Report)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Recommended Stories

Institutional Ownership by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.